There were 777 press releases posted in the last 24 hours and 167,579 in the last 365 days.

India Pharma 2017 Market Company Profile,Capacity,Production,Price,Cost,Gross and Revenue Market Report

PUNE, INDIA, January 11, 2017 /EINPresswire.com/ --

WiseGuyReports.Com Publish a New Market Research Report On – “India Pharma 2017 Market Company Profile,Capacity,Production,Price,Cost,Gross and Revenue Market Report”.

2016 will be a crucial for drug makers and consumers. During ‘Make-in-India’ week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug discovery, to promote manufacturing of certain drugs against life threatening diseases like AIDS, and to reduce our dependence on China, the Govt. has promised to offer many incentives (exemption from excise duty or tax) and also plans to setup venture capital funds, cluster developments to strengthen pharma infrastructure / business. Other developments or initiatives include, i) The voluntary Uniform code of Pharma marketing practice will be replaced with a mandatory code by June.

This will stop the promotion of drug prior to receipt of the marketing approval and also the practice of drug makers offering gifts to doctors upon prescribing their products; ii) Concept of the ‘Online pharmacies’ is also expected to be implemented during this year; iii) Change in FDI rule where investor now invest thru Automatic route rather taking any prior regulatory approval; iv) Growth in Medical Infrastructure which will increase accessibility to drug market to improve in Tier-II towns and rural areas.

Download Sample Report @ https://www.wiseguyreports.com/sample-request/375960-india-pharma-outlook-2016-milestones-to-watch-growth-from-exports-and-domestic-getting-better-implementation-of-policies-under-make-in-india-overture-of-a-new-ministry

For more information or any query mail at sales@wiseguyreports.com

Declined growth in bulk drugs due to regulatory scrutiny and rising competition & market factors from other Asian competing nations will be compensated by geographies expansion (e.g., Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases’ segment, due to growth in urban population, better awareness on healthcare, and greater penetration of services. India pharma has started expanding in other regulated markets (Japan, Germany, France, Canada) and Tier-II countries (Brazil, Mexico, Venezuela, Russia, etc.). To explore further opportunities of growth, Indian pharma companies have started developing complex generics/ biosimilars. Almost all companies, among Top-20 list, have robust pipeline in this value chain, targeting primarily emerging markets; however, they are also capitalizing on their competitiveness and capabilities to enter into the regulated market.

Complete Report Details @ https://www.wiseguyreports.com/reports/375960-india-pharma-outlook-2016-milestones-to-watch-growth-from-exports-and-domestic-getting-better-implementation-of-policies-under-make-in-india-overture-of-a-new-ministry

Table Of Contents – Major Key Points

Aurobindo Pharma - US BUSINESS AND INJECTABLES KEYS TO GROWTH – Looking to STRENGTHEN IN OTHER GEOGRAPHY TOO
Table 1 : Aurobindo Pharma : GLOBAL REGULATORY FILINGS
Table 2 : Aurobindo Pharma KEY ANDAs APPROVAL IN 1H16
New Aeras to Watch For :
CADILA HEALTHCARE LTD : Future growth from NCE, Bio-Similars, Vaccines, Transdermal and Complex Generics

- US REMAINS THE KEY GROWTH DRIVER FOR CDH
- Table 1
Cadila Healthcare Ltd.
KEY TRANSDERMAL PRODUCTS
- ONGOING STUDIES OF LIPAGLYN IN NASH
- Clinical Data in NASH so far
- Clinical Data in NASH so far
Cipla Ltd : Consolidation of Recent Acquisitions + Geographic Expansion of the Inhaler Business
-Figure 1
Cipla Ltd.
GENERIC NEXIUM’S MARKET SHARE TREND
- Table 1
Cipla Ltd.
INVAGEN’S SELECT PARA IV OPPORTUNITIES
- Table 2
Cipla Ltd.
INVAGEN: HIGHEST MARKET SHARE PRODUCTS – TOP 5
- Annexure : Cipla Ltd.
INVAGEN’S CURRENT PRODUCTS
- DR REDDY’S LAB : Near-term Growth Muted: Strong Competition to Launched Products + No Significant Approvals + Remediation Costs related to FDA’s WL
- Figure 1
Dr. Reddy’s Lab
PENDING ANDAs(76) BY DOSAGE FORM& SELECT OPPORTUNITIES
- Table 1
Dr Reddy’s Ltd.
FACING COMPETITION IN US: MARKET SHARE OF KEY INJECTABLES
-Figure 2
Dr. Reddy’s Lab
AURIGENE: INTERNAL PIPELINE
- ANNEXURE : Key highlights of the warning letter

……..CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Check Discount On This Report @ https://www.wiseguyreports.com/check-discount/375960-india-pharma-outlook-2016-milestones-to-watch-growth-from-exports-and-domestic-getting-better-implementation-of-policies-under-make-in-india-overture-of-a-new-ministry

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here